Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of HRS-1597 in Healthy and Obese Participants
NCT07808918Phase 1Not yet recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-1597 in obesity (2 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Incidence of adverse events (AE) and serious adverse events (SAE) at 41 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
HRS-1597
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07808918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07808918.